Cancer Communications

Papers
(The H4-Index of Cancer Communications is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Issue Information750
Issue Information450
403
263
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity248
Issue Information237
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort214
189
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation173
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma171
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma155
Age‐specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross‐sectional study153
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study144
Kindlin‐1 drives early steps of breast cancer metastasis135
Current status and perspectives of esophageal cancer: a comprehensive review135
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update134
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy134
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives130
Issue Information108
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h106
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica103
P300/CBP‐associated factor (PCAF)‐mediated acetylation of Fascin at lysine 471 inhibits its actin‐bundling activity and tumor metastasis in esophageal cancer103
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer99
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases98
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study97
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward96
Research trends of cancer metabolism: analysis from a Chinese perspective92
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer91
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions89
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial87
85
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program76
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity74
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer74
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates74
N6‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastasis70
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses67
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence61
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy59
Issue Information58
57
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma56
Association between antipsychotic agents and risk of lung cancer: a nested case‐control study50
47
A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX247
Cover Image, Volume 42, Issue 147
0.068351984024048